Abstract
Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.
MeSH terms
-
Chemistry, Pharmaceutical
-
Drug-Related Side Effects and Adverse Reactions
-
Epoetin Alfa
-
Erythropoietin / administration & dosage
-
Erythropoietin / adverse effects
-
Erythropoietin / chemistry
-
Erythropoietin / immunology
-
Hematinics / administration & dosage
-
Hematinics / adverse effects*
-
Hematinics / chemistry
-
Hematinics / immunology*
-
Humans
-
Immune Tolerance
-
Protein Multimerization / immunology
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / chemistry
-
Recombinant Proteins / immunology
-
Red-Cell Aplasia, Pure / etiology*
-
Red-Cell Aplasia, Pure / immunology*
-
Renal Insufficiency, Chronic / diagnosis
-
Renal Insufficiency, Chronic / drug therapy*
-
Renal Insufficiency, Chronic / therapy
-
Time Factors
Substances
-
Hematinics
-
Recombinant Proteins
-
Erythropoietin
-
Epoetin Alfa